Alira Health

We Announce role as Strategic Advisor to Gener8 on its Acquisition of Symbient

Alira Health’s Strategy Consulting and Transaction Advisory practices collaborate to help Gener8 grow beyond its core business.

News
Published on:
March 11, 2020

MUNICH, GERMANY – MARCH 11, 2020 – Alira Health, a leading international healthcare and life sciences advisory firm, was selected as the strategic advisor to Gener8, a Sunnyvale, California-based engineering and manufacturing firm serving the life sciences and medical device industries, in their acquisition of Symbient Product Development, LLC, a leading provider of design engineering for polymer life sciences consumables, based in Carlsbad, California. Gener8 is a portfolio company of Sverica Capital Management LP.

“The team at Symbient has built a tremendous business, taking on high complexity engineering projects with best-in-class turnaround times,” said David Brakenwagen, Gener8 CEO. “We are already collaborating on a number of customer programs which are yielding great success and are excited to provide this differentiated end market solution with the decades of combined technology, know-how and experience.”

“We are proud to support Gener8 in a transaction that allows them to offer customers a complete turnkey instrument and consumable solution,” says Dr. Michal Raciborski, Partner, Alira Health. “Our Strategy Consulting practice performed a comprehensive commercial due diligence on Symbient and its major markets to support Gener8’s evaluation of the transaction’s commercial value proposition and related opportunities and risks. Our team is dedicated to identifying and executing on these types of synergistic opportunities that deliver long-term profitability and value for our clients.”

“Congratulations to Gener8 and Symbient on a transaction that will bring even greater innovation to the product development and contract manufacturing markets. We have unique expertise in the CDMO space with transaction and market knowledge and direct contact with major players and potential targets around the world,” says Carlo Stimamiglio, Partner, Alira Health. “Our strong track record in M&A and strategy consulting assignments makes Alira Health the ideal choice for clients who need support on the definition and implementation of their growth strategies.”

About Gener8:

Gener8, founded in 2002, offers full product lifecycle engineering and manufacturing for highly complex instruments and products within the highly regulated Life Sciences and Medical Device markets. The services that Gener8 provides allow for an agile and fast time to market solution that results in high reliability solutions for customers. With locations in Sunnyvale, CA and Boston, MA Gener8 operates in the corridors of innovation and maintains all industry specific certifications.

For more information, please visit www.gener8.net.

Related news

Events April 1, 2025
The Medtech Forum 2025
Connect with our experts to learn how we can help accelerate patient access to your innovations.
EU HEOR MedTech Pricing
Articles March 17, 2025
Heart Failure Medical Devices Market Landscape in 2025
Explore the forces shaping heart failure medical devices, the emerging technologies driving innovation, and the key challenges on the road ahead.
Cardiology Medical Devices MedTech
Events February 13, 2025
Medtech Summit Budapest 2025
Learn how can we help you optimize your regulatory strategy and navigate country-specific regulatory requirements.
EU MedTech
Events February 3, 2025
Technology and Heart Failure Therapeutics Conference 2025
Look for our cardiovascular experts onsite in Boston to discuss your development support needs.
CDMO Medical Devices MedTech
Uncategorized January 23, 2025
The 2025 Global Medtech Contract Manufacturing Report
Discover the trends in the world of medical device CDMOs and their meaning for the industry in 2025 and beyond.
CDMO MedTech
Events January 15, 2025
MD&M West 2025
Join our Coffee Talk session “Private Equity Buy-and-Build Strategies in Medtech CDMO” on Tuesday, February 4 at MD&M West.
CDMO Medical Devices MedTech
News December 17, 2024
Alira Health Secures Up to $100M Growth Debt Facility from Symbiotic Capital to Propel Strategic Expansion and Patient-Enabled Innovation
This funding will drive Alira Health’s strategic growth, enhance its innovative technology platforms, and support solutions that empower patients and create value for life sciences companies.
Biopharma Life Sciences MedTech Patient-Enabled Innovation Strategic Expansion
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.